Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Debt: 2017-2021

Historic Non-Current Debt for Sunshine Biopharma (SBFM) over the last 2 years, with Dec 2021 value amounting to $1.9 million.

  • Sunshine Biopharma's Non-Current Debt rose 100.21% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.9 million, marking a year-over-year increase of 100.21%. This contributed to the annual value of $1.9 million for FY2021, which is 100.21% up from last year.
  • As of Q4 2021, Sunshine Biopharma's Non-Current Debt stood at $1.9 million, which was down 40.70% from $3.2 million recorded in Q3 2021.
  • Over the past 5 years, Sunshine Biopharma's Non-Current Debt peaked at $3.2 million during Q3 2021, and registered a low of $63,234 during Q2 2020.
  • Its 3-year average for Non-Current Debt is $1.5 million, with a median of $1.9 million in 2021.
  • Data for Sunshine Biopharma's Non-Current Debt shows a peak YoY spiked of 3,148.59% (in 2021) over the last 5 years.
  • Over the past 5 years, Sunshine Biopharma's Non-Current Debt (Quarterly) stood at $79,710 in 2017, then surged by 263.63% to $289,847 in 2018, then reached $289,825 in 2019, then reached $949,006 in 2020, then skyrocketed by 100.21% to $1.9 million in 2021.
  • Its last three reported values are $1.9 million in Q4 2021, $3.2 million for Q3 2021, and $2.1 million during Q2 2021.